Clinical Trials · NCT03482024
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 45
- Start date
- Mar 2018
- Locations
- 4 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])